PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells

Michaela J. Higgins, Julia Beaver, Hong Yuen Wong, John P. Gustin, Josh D. Lauring, Joseph P. Garay, Hiroyuki Konishi, Morassa Mohseni, Grace M. Wang, Justin Cidado, Danijela Jelovac, David P. Cosgrove, Akina Tamaki, Abde M. Abukhdeir, Ben Ho Park

Research output: Contribution to journalArticle

Abstract

A high frequency of somatic mutations has been found in breast cancers within the gene encoding the catalytic p110α subunit of PI3K, PIK3CA. Using isogenic human breast epithelial cells, we have previously demonstrated that oncogenic PIK3CA "hotspot" mutations predict for response to the toxic effects of lithium. However, other somatic genetic alterations occur within this pathway in breast cancers, and it is possible that these changes may also predict for lithium sensitivity. We overexpressed the epidermal growth factor receptor (EGFR) into the non-tumorigenic human breast epithelial cell line MCF-10A, and compared these cells to isogenic cell lines previously created via somatic cell gene targeting to model Pten loss, PIK3CA mutations, and the invariant AKT1 mutation, E17K. EGFR overexpressing clones were capable of cellular proliferation in the absence of EGF and were sensitive to lithium similar to the results previously seen with cells harboring PIK3CA mutations. In contrast, AKT1 E17K cells and PTEN-/- cells displayed resistance or partial sensitivity to lithium, respectively. Western blot analysis demonstrated that lithium sensitivity correlated with significant decreases in both PI3K and MAPK signaling that were observed only in EGFR overexpressing and mutant PIK3CA cell lines. These studies demonstrate that EGFR overexpression and PIK3CA mutations are predictors of response to lithium, whereas Pten loss and AKT1 E17K mutations do not predict for lithium sensitivity. Our findings may have important implications for the use of these genetic lesions in breast cancer patients as predictive markers of response to emerging PI3K pathway inhibitors.

Original languageEnglish (US)
Pages (from-to)358-367
Number of pages10
JournalCancer Biology and Therapy
Volume11
Issue number3
DOIs
StatePublished - Feb 1 2011

Fingerprint

Lithium
Epidermal Growth Factor Receptor
Breast
Epithelial Cells
Mutation
Phosphatidylinositol 3-Kinases
Breast Neoplasms
Cell Line
Gene Targeting
Poisons
Neoplasm Genes
Mutation Rate
Epidermal Growth Factor
Catalytic Domain
Clone Cells
Western Blotting
Cell Proliferation

Keywords

  • AKT
  • Breast cancer
  • EGFR
  • PI3K
  • Pten

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells. / Higgins, Michaela J.; Beaver, Julia; Wong, Hong Yuen; Gustin, John P.; Lauring, Josh D.; Garay, Joseph P.; Konishi, Hiroyuki; Mohseni, Morassa; Wang, Grace M.; Cidado, Justin; Jelovac, Danijela; Cosgrove, David P.; Tamaki, Akina; Abukhdeir, Abde M.; Park, Ben Ho.

In: Cancer Biology and Therapy, Vol. 11, No. 3, 01.02.2011, p. 358-367.

Research output: Contribution to journalArticle

Higgins, MJ, Beaver, J, Wong, HY, Gustin, JP, Lauring, JD, Garay, JP, Konishi, H, Mohseni, M, Wang, GM, Cidado, J, Jelovac, D, Cosgrove, DP, Tamaki, A, Abukhdeir, AM & Park, BH 2011, 'PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells', Cancer Biology and Therapy, vol. 11, no. 3, pp. 358-367. https://doi.org/10.4161/cbt.11.3.14227
Higgins, Michaela J. ; Beaver, Julia ; Wong, Hong Yuen ; Gustin, John P. ; Lauring, Josh D. ; Garay, Joseph P. ; Konishi, Hiroyuki ; Mohseni, Morassa ; Wang, Grace M. ; Cidado, Justin ; Jelovac, Danijela ; Cosgrove, David P. ; Tamaki, Akina ; Abukhdeir, Abde M. ; Park, Ben Ho. / PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells. In: Cancer Biology and Therapy. 2011 ; Vol. 11, No. 3. pp. 358-367.
@article{8c80333b906549f2a57f07167d4313c9,
title = "PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells",
abstract = "A high frequency of somatic mutations has been found in breast cancers within the gene encoding the catalytic p110α subunit of PI3K, PIK3CA. Using isogenic human breast epithelial cells, we have previously demonstrated that oncogenic PIK3CA {"}hotspot{"} mutations predict for response to the toxic effects of lithium. However, other somatic genetic alterations occur within this pathway in breast cancers, and it is possible that these changes may also predict for lithium sensitivity. We overexpressed the epidermal growth factor receptor (EGFR) into the non-tumorigenic human breast epithelial cell line MCF-10A, and compared these cells to isogenic cell lines previously created via somatic cell gene targeting to model Pten loss, PIK3CA mutations, and the invariant AKT1 mutation, E17K. EGFR overexpressing clones were capable of cellular proliferation in the absence of EGF and were sensitive to lithium similar to the results previously seen with cells harboring PIK3CA mutations. In contrast, AKT1 E17K cells and PTEN-/- cells displayed resistance or partial sensitivity to lithium, respectively. Western blot analysis demonstrated that lithium sensitivity correlated with significant decreases in both PI3K and MAPK signaling that were observed only in EGFR overexpressing and mutant PIK3CA cell lines. These studies demonstrate that EGFR overexpression and PIK3CA mutations are predictors of response to lithium, whereas Pten loss and AKT1 E17K mutations do not predict for lithium sensitivity. Our findings may have important implications for the use of these genetic lesions in breast cancer patients as predictive markers of response to emerging PI3K pathway inhibitors.",
keywords = "AKT, Breast cancer, EGFR, PI3K, Pten",
author = "Higgins, {Michaela J.} and Julia Beaver and Wong, {Hong Yuen} and Gustin, {John P.} and Lauring, {Josh D.} and Garay, {Joseph P.} and Hiroyuki Konishi and Morassa Mohseni and Wang, {Grace M.} and Justin Cidado and Danijela Jelovac and Cosgrove, {David P.} and Akina Tamaki and Abukhdeir, {Abde M.} and Park, {Ben Ho}",
year = "2011",
month = "2",
day = "1",
doi = "10.4161/cbt.11.3.14227",
language = "English (US)",
volume = "11",
pages = "358--367",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells

AU - Higgins, Michaela J.

AU - Beaver, Julia

AU - Wong, Hong Yuen

AU - Gustin, John P.

AU - Lauring, Josh D.

AU - Garay, Joseph P.

AU - Konishi, Hiroyuki

AU - Mohseni, Morassa

AU - Wang, Grace M.

AU - Cidado, Justin

AU - Jelovac, Danijela

AU - Cosgrove, David P.

AU - Tamaki, Akina

AU - Abukhdeir, Abde M.

AU - Park, Ben Ho

PY - 2011/2/1

Y1 - 2011/2/1

N2 - A high frequency of somatic mutations has been found in breast cancers within the gene encoding the catalytic p110α subunit of PI3K, PIK3CA. Using isogenic human breast epithelial cells, we have previously demonstrated that oncogenic PIK3CA "hotspot" mutations predict for response to the toxic effects of lithium. However, other somatic genetic alterations occur within this pathway in breast cancers, and it is possible that these changes may also predict for lithium sensitivity. We overexpressed the epidermal growth factor receptor (EGFR) into the non-tumorigenic human breast epithelial cell line MCF-10A, and compared these cells to isogenic cell lines previously created via somatic cell gene targeting to model Pten loss, PIK3CA mutations, and the invariant AKT1 mutation, E17K. EGFR overexpressing clones were capable of cellular proliferation in the absence of EGF and were sensitive to lithium similar to the results previously seen with cells harboring PIK3CA mutations. In contrast, AKT1 E17K cells and PTEN-/- cells displayed resistance or partial sensitivity to lithium, respectively. Western blot analysis demonstrated that lithium sensitivity correlated with significant decreases in both PI3K and MAPK signaling that were observed only in EGFR overexpressing and mutant PIK3CA cell lines. These studies demonstrate that EGFR overexpression and PIK3CA mutations are predictors of response to lithium, whereas Pten loss and AKT1 E17K mutations do not predict for lithium sensitivity. Our findings may have important implications for the use of these genetic lesions in breast cancer patients as predictive markers of response to emerging PI3K pathway inhibitors.

AB - A high frequency of somatic mutations has been found in breast cancers within the gene encoding the catalytic p110α subunit of PI3K, PIK3CA. Using isogenic human breast epithelial cells, we have previously demonstrated that oncogenic PIK3CA "hotspot" mutations predict for response to the toxic effects of lithium. However, other somatic genetic alterations occur within this pathway in breast cancers, and it is possible that these changes may also predict for lithium sensitivity. We overexpressed the epidermal growth factor receptor (EGFR) into the non-tumorigenic human breast epithelial cell line MCF-10A, and compared these cells to isogenic cell lines previously created via somatic cell gene targeting to model Pten loss, PIK3CA mutations, and the invariant AKT1 mutation, E17K. EGFR overexpressing clones were capable of cellular proliferation in the absence of EGF and were sensitive to lithium similar to the results previously seen with cells harboring PIK3CA mutations. In contrast, AKT1 E17K cells and PTEN-/- cells displayed resistance or partial sensitivity to lithium, respectively. Western blot analysis demonstrated that lithium sensitivity correlated with significant decreases in both PI3K and MAPK signaling that were observed only in EGFR overexpressing and mutant PIK3CA cell lines. These studies demonstrate that EGFR overexpression and PIK3CA mutations are predictors of response to lithium, whereas Pten loss and AKT1 E17K mutations do not predict for lithium sensitivity. Our findings may have important implications for the use of these genetic lesions in breast cancer patients as predictive markers of response to emerging PI3K pathway inhibitors.

KW - AKT

KW - Breast cancer

KW - EGFR

KW - PI3K

KW - Pten

UR - http://www.scopus.com/inward/record.url?scp=79951526724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951526724&partnerID=8YFLogxK

U2 - 10.4161/cbt.11.3.14227

DO - 10.4161/cbt.11.3.14227

M3 - Article

C2 - 21124076

AN - SCOPUS:79951526724

VL - 11

SP - 358

EP - 367

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 3

ER -